SCHEMBL650485

SCHEMBL650485

CC(=O)Nc1ncc(C=C2SC(=Nc3ccc4c(ccn4C)c3)NC2=O)s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 0.44
KMT2A Q03164 11/20 0.44
MEN1 O00255 10/20 0.44
RAB9A P51151 3/20 0.44
MAPK1 P28482 1/20 0.44
HCRTR1 O43613 1/20 0.42
POLB P06746 4/20 0.42
ALDH1A1 P00352 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40
NPC1 O15118 1/20 0.40
LMNA P02545 2/20 0.40
CDC25A P30304 3/20 0.40
CDC25B P30305 3/20 0.40
IDE P14735 1/20 0.40
HTT P42858 1/20 0.40
PSMD14 O00487 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
APOBEC3A P31941 1/20 0.39
APOBEC3G Q9HC16 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL650484 1.00 MAPT (0.44) MAPTKMT2AMEN1RAB9AMAPK1
SCHEMBL10226229 1.00 MAPT (0.44) MAPTKMT2AMEN1RAB9AMAPK1
SCHEMBL650977 0.93 MAPT (0.44) MAPTKMT2AMEN1RAB9AMAPK1
SCHEMBL10227762 0.93 MAPT (0.44) MAPTKMT2AMEN1RAB9AMAPK1
SCHEMBL650976 0.93 MAPT (0.44) MAPTKMT2AMEN1RAB9AMAPK1
SCHEMBL10176135 0.91 MAPT (0.42) MAPTKMT2AMEN1RAB9AMAPK1
SCHEMBL10227576 0.85 MAPT (0.42) MAPTKMT2AMEN1RAB9AMAPK1
SCHEMBL649187 0.85 MAPT (0.42) MAPTKMT2AMEN1RAB9AMAPK1
SCHEMBL648798 0.85 MAPT (0.42) MAPTKMT2AMEN1RAB9AMAPK1
SCHEMBL651290 0.84 OGA (0.47) MAPTKMT2AMEN1RAB9AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 MAPT 3657/4885KMT2A 3437/4885MEN1 1406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.